培哚普利和卡维地洛对自发性高血压大鼠Ang Ⅱ和B型利钠肽的影响
Perindopril and Carvedilol on Ventricular Ang Ⅱ and BNP
-
摘要: 目的 转换酶抑制剂 (ACEI)培哚普利和β -阻滞剂 (BB)卡维地洛逆转左室肥大 (LVH) ,本文旨在探讨药物干预下自发性高血压大鼠 (SHR)血管紧张素 (AngⅡ )和B型利钠肽 (BNP)水平改变的意义。 方法 15周龄雄性SHR尾动脉测压 ,随机分三组 :未治疗组 (n =7)、培哚普利组 (n =6 )、卡维地洛组 (n =7)。药物溶于蒸馏水以灌胃法给予 ,培哚普利 8mg/kg·-1、卡维地洛 4mg/kg·-1,疗程 6周 ,未治疗组以等量蒸馏水灌胃。 15周龄雄性WKY大鼠为正常血压对照组 (n =8)。实验结束断头处死 ,取血、分离左心室。采用高效液相色谱 -放射免疫 (HPLC RIA)分析技术和RIA法测定各组大鼠血浆和心肌组织AngⅡ和BNP(B型利钠肽 )浓度。 结果 (1)经 6周治疗后SHR血压和左心室/体重比值较未治疗组有显著下降 (P <0 0 5 ) ;(2 )培哚普利能显著降低心肌组织AngⅡ水平 (P <0 0 5 ) ,但能明显升高血浆AngⅡ水平 (P <0 0 5 ) ;(3)卡维地洛显著降低血浆和心肌组织AngⅡ水平 (P <0 0 5 ) ;(4)无论培哚普利、卡维地洛都能使血浆和心肌组织的BNP水平降低 (P <0 0 5 )。结论 培哚普利、卡维地洛逆转LVH与其降低心肌组织AngⅡ相一致 ,BNP可看作是AngⅡ的天然拮抗物 ,随LVH逆转而下降 ,BNP下降反映治疗有效。Abstract: Objective This study aims to investigate whether the change of ventricular Ang Ⅱ and BNP levels is involved in the reverse effect of perindopril and carvedilol on ventricular hypertrophy. Methods Twenty 15 week-old male SHRs were divided into three groups: perindopril group ( n =6,8 mg/kg·d -1 ),carvedilol group ( n =7,4 mg/kg·d -1 ) and sham group ( n =7). In each group drugs or equal volume of distill water were administered respectively for 6 weeks by gavage. We also used eight age matched WKY as a control group. We measured angiotensin Ⅱ (Ang Ⅱ) and B type natriuretic peptide(BNP) level in rat left ventricular and plasma by high performance liquid chromatography-radioimmunoassay technique (HPLC-RIA) and radioimmunoassay assay(RIA). Results (1)Perindopril and carvedilol decrease the blood pressure and LV/BW ratio after six weeks treatment ( P <0.05);(2) Perindopril significantly decrease the ventricular Ang Ⅱ level ( P <0.05),but markely increased plasma Ang Ⅱ level ( P <0.05);(3) Carvedilol significantly decrease plasma and ventricular Ang Ⅱ level ( P <0.05);(4) Both perindopril and carvedilol decrease ventricular and plasma BNP level ( P <0.05). Conclusion Perindopril and carvedilol reverse left ventricular hypertrophy which was in associated to the decreases in ventricular Ang Ⅱ level;BNP level might serve as a therapeutic index for reversal of ventricular hypertrophy.